ID   DDR1_HUMAN              Reviewed;         913 AA.
AC   Q08345; B5A975; B5A976; B7Z2K0; Q14196; Q16562; Q2L6H3; Q4LE50;
AC   Q5ST11; Q5ST12; Q6NSK4; Q9UD35; Q9UD36; Q9UD37; Q9UD86; Q9UDL2;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DT   10-MAY-2017, entry version 193.
DE   RecName: Full=Epithelial discoidin domain-containing receptor 1;
DE            Short=Epithelial discoidin domain receptor 1;
DE            EC=2.7.10.1;
DE   AltName: Full=CD167 antigen-like family member A;
DE   AltName: Full=Cell adhesion kinase;
DE   AltName: Full=Discoidin receptor tyrosine kinase;
DE   AltName: Full=HGK2;
DE   AltName: Full=Mammary carcinoma kinase 10;
DE            Short=MCK-10;
DE   AltName: Full=Protein-tyrosine kinase 3A;
DE   AltName: Full=Protein-tyrosine kinase RTK-6;
DE   AltName: Full=TRK E;
DE   AltName: Full=Tyrosine kinase DDR;
DE   AltName: Full=Tyrosine-protein kinase CAK;
DE   AltName: CD_antigen=CD167a;
DE   Flags: Precursor;
GN   Name=DDR1; Synonyms=CAK, EDDR1, NEP, NTRK4, PTK3A, RTK6, TRKE;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Keratinocyte;
RX   PubMed=8226977;
RA   di Marco E., Cutuli N., Guerra L., Cancedda R., de Luca M.;
RT   "Molecular cloning of trkE, a novel trk-related putative tyrosine
RT   kinase receptor isolated from normal human keratinocytes and widely
RT   expressed by normal human tissues.";
RL   J. Biol. Chem. 268:24290-24295(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT VAL-833.
RC   TISSUE=Placenta;
RX   PubMed=8390675; DOI=10.1073/pnas.90.12.5677;
RA   Johnson J.D., Edman J.C., Rutter W.J.;
RT   "A receptor tyrosine kinase found in breast carcinoma cells has an
RT   extracellular discoidin I-like domain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5677-5681(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Ovary;
RX   PubMed=7848919;
RA   Laval S., Butler R., Shelling A.N., Hanby A.M., Poulsom R.,
RA   Ganesan T.S.;
RT   "Isolation and characterization of an epithelial-specific receptor
RT   tyrosine kinase from an ovarian cancer cell line.";
RL   Cell Growth Differ. 5:1173-1183(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal liver;
RX   PubMed=8302582;
RA   Perez J.L., Shen X., Finkernagel S., Sciorra L., Jenkins N.A.,
RA   Gilbert D.J., Copeland N.G., Wong T.W.;
RT   "Identification and chromosomal mapping of a receptor tyrosine kinase
RT   with a putative phospholipid binding sequence in its ectodomain.";
RL   Oncogene 9:211-219(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-833.
RX   PubMed=8977099; DOI=10.1016/S0014-5793(96)01234-3;
RA   Sakuma S., Tada M., Saya H., Sawamura Y., Shinohe Y., Abe H.;
RT   "Receptor protein tyrosine kinase DDR is up-regulated by p53
RT   protein.";
RL   FEBS Lett. 398:165-169(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8796349; DOI=10.1101/gr.6.7.620;
RA   Playford M.P., Butler R.J., Wang X.C., Katso R.M., Cooke I.E.,
RA   Ganesan T.S.;
RT   "The genomic structure of discoidin receptor tyrosine kinase.";
RL   Genome Res. 6:620-627(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Lung;
RX   PubMed=8622863;
RA   Perez J.L., Jing S.Q., Wong T.W.;
RT   "Identification of two isoforms of the Cak receptor kinase that are
RT   coexpressed in breast tumor cell lines.";
RL   Oncogene 12:1469-1477(1996).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND NUCLEOTIDE SEQUENCE [MRNA]
RP   OF 1-286 (ISOFORMS 1/2/4).
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 5).
RC   TISSUE=Brain, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M.,
RA   Ohara R., Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long
RT   cDNAs encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   TISSUE=Peripheral blood leukocyte;
RX   PubMed=16702430; DOI=10.1534/genetics.106.057034;
RA   Shiina T., Ota M., Shimizu S., Katsuyama Y., Hashimoto N., Takasu M.,
RA   Anzai T., Kulski J.K., Kikkawa E., Naruse T., Kimura N., Yanagiya K.,
RA   Watanabe A., Hosomichi K., Kohara S., Iwamoto C., Umehara Y.,
RA   Meyer A., Wanner V., Sano K., Macquin C., Ikeo K., Tokunaga K.,
RA   Gojobori T., Inoko H., Bahram S.;
RT   "Rapid evolution of major histocompatibility complex class I genes in
RT   primates generates new disease alleles in humans via hitchhiking
RT   diversity.";
RL   Genetics 173:1555-1570(2006).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   PROTEIN SEQUENCE OF 480-490; 515-525 AND 790-798, IDENTIFICATION BY
RP   MASS SPECTROMETRY, SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT
RP   TYR-484; TYR-513; TYR-520; TYR-792; TYR-796 AND TYR-797, GLYCOSYLATION
RP   AT ASN-211 AND ASN-260, AND MUTAGENESIS OF ARG-105; ASN-211; SER-213;
RP   ASN-260; ASN-371; THR-379; THR-393; ASN-394 AND LYS-655.
RX   PubMed=24509848; DOI=10.1074/jbc.M113.541102;
RA   Fu H.L., Valiathan R.R., Payne L., Kumarasiri M., Mahasenan K.V.,
RA   Mobashery S., Huang P., Fridman R.;
RT   "Glycosylation at Asn211 regulates the activation state of the
RT   discoidin domain receptor 1 (DDR1).";
RL   J. Biol. Chem. 289:9275-9287(2014).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 501-550 (ISOFORMS 1/4), NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 501-550 AND 651-694 (ISOFORM 2), NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 651-694 (ISOFORM 4), ALTERNATIVE SPLICING, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=7845687;
RA   Alves F., Vogel W., Mossie K., Millauer B., Hoefler H., Ullrich A.;
RT   "Distinct structural characteristics of discoidin I subfamily receptor
RT   tyrosine kinases and complementary expression in human cancer.";
RL   Oncogene 10:609-618(1995).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 771-824 (ISOFORMS 1/2/4).
RX   PubMed=7834423; DOI=10.1007/BF02303537;
RA   Weiner T.M., Liu E.T., Craven R.J., Cance W.G.;
RT   "Expression of growth factor receptors, the focal adhesion kinase, and
RT   other tyrosine kinases in human soft tissue tumors.";
RL   Ann. Surg. Oncol. 1:18-27(1994).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 772-823 (ISOFORMS 1/2/4), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Melanocyte;
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [19]
RP   FUNCTION AS COLLAGEN RECEPTOR, PHOSPHORYLATION AT TYR-513, INTERACTION
RP   WITH SHC1, AUTOPHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=9659899; DOI=10.1016/S1097-2765(00)80003-9;
RA   Vogel W., Gish G.D., Alves F., Pawson T.;
RT   "The discoidin domain receptor tyrosine kinases are activated by
RT   collagen.";
RL   Mol. Cell 1:13-23(1997).
RN   [20]
RP   FUNCTION.
RX   PubMed=12065315; DOI=10.1161/01.RES.0000022166.74073.F8;
RA   Hou G., Vogel W.F., Bendeck M.P.;
RT   "Tyrosine kinase activity of discoidin domain receptor 1 is necessary
RT   for smooth muscle cell migration and matrix metalloproteinase
RT   expression.";
RL   Circ. Res. 90:1147-1149(2002).
RN   [21]
RP   FUNCTION, INTERACTION WITH PTPN11 AND NCK2, PHOSPHORYLATION AT
RP   TYR-740, AND MUTAGENESIS OF TYR-740.
RX   PubMed=16337946; DOI=10.1016/j.febslet.2005.11.035;
RA   Koo D.H., McFadden C., Huang Y., Abdulhussein R., Friese-Hamim M.,
RA   Vogel W.F.;
RT   "Pinpointing phosphotyrosine-dependent interactions downstream of the
RT   collagen receptor DDR1.";
RL   FEBS Lett. 580:15-22(2006).
RN   [22]
RP   FUNCTION.
RX   PubMed=16234985; DOI=10.1007/s11060-005-6874-1;
RA   Ram R., Lorente G., Nikolich K., Urfer R., Foehr E., Nagavarapu U.;
RT   "Discoidin domain receptor-1a (DDR1a) promotes glioma cell invasion
RT   and adhesion in association with matrix metalloproteinase-2.";
RL   J. Neurooncol. 76:239-248(2006).
RN   [23]
RP   INTERACTION WITH WWC1 AND PRKCZ.
RX   PubMed=18190796; DOI=10.1016/j.bbamcr.2007.12.007;
RA   Hilton H.N., Stanford P.M., Harris J., Oakes S.R., Kaplan W.,
RA   Daly R.J., Ormandy C.J.;
RT   "KIBRA interacts with discoidin domain receptor 1 to modulate
RT   collagen-induced signalling.";
RL   Biochim. Biophys. Acta 1783:383-393(2008).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND INTERACTION
RP   WITH MYH9.
RX   PubMed=19401332; DOI=10.1242/jcs.046219;
RA   Huang Y., Arora P., McCulloch C.A., Vogel W.F.;
RT   "The collagen receptor DDR1 regulates cell spreading and motility by
RT   associating with myosin IIA.";
RL   J. Cell Sci. 122:1637-1646(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH CDH1.
RX   PubMed=20432435; DOI=10.1002/jcp.22134;
RA   Eswaramoorthy R., Wang C.K., Chen W.C., Tang M.J., Ho M.L.,
RA   Hwang C.C., Wang H.M., Wang C.Z.;
RT   "DDR1 regulates the stabilization of cell surface E-cadherin and E-
RT   cadherin-mediated cell aggregation.";
RL   J. Cell. Physiol. 224:387-397(2010).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH SRC.
RX   PubMed=20093046; DOI=10.1016/j.carpath.2009.12.006;
RA   Lu K.K., Trcka D., Bendeck M.P.;
RT   "Collagen stimulates discoidin domain receptor 1-mediated migration of
RT   smooth muscle cells through Src.";
RL   Cardiovasc. Pathol. 20:71-76(2011).
RN   [28]
RP   FUNCTION.
RX   PubMed=20884741; DOI=10.1183/09031936.00039710;
RA   Roberts M.E., Magowan L., Hall I.P., Johnson S.R.;
RT   "Discoidin domain receptor 1 regulates bronchial epithelial repair and
RT   matrix metalloproteinase production.";
RL   Eur. Respir. J. 37:1482-1493(2011).
RN   [29]
RP   FUNCTION AS COLLAGEN RECEPTOR, AND AUTOPHOSPHORYLATION.
RX   PubMed=21044884; DOI=10.1016/j.matbio.2010.10.004;
RA   Xu H., Raynal N., Stathopoulos S., Myllyharju J., Farndale R.W.,
RA   Leitinger B.;
RT   "Collagen binding specificity of the discoidin domain receptors:
RT   binding sites on collagens II and III and molecular determinants for
RT   collagen IV recognition by DDR1.";
RL   Matrix Biol. 30:16-26(2011).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 29-367 IN COMPLEX WITH
RP   INHIBITORY ANTIBODY, SUBUNIT, CALCIUM-BINDING SITES, GLYCOSYLATION AT
RP   ASN-211 AND ASN-260, AND DISULFIDE BONDS.
RX   PubMed=22483115; DOI=10.1016/j.str.2012.02.011;
RA   Carafoli F., Mayer M.C., Shiraishi K., Pecheva M.A., Chan L.Y.,
RA   Nan R., Leitinger B., Hohenester E.;
RT   "Structure of the discoidin domain receptor 1 extracellular region
RT   bound to an inhibitory Fab fragment reveals features important for
RT   signaling.";
RL   Structure 20:688-697(2012).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 601-913 IN COMPLEX WITH
RP   INHIBITOR, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF GLY-707.
RX   PubMed=23899692; DOI=10.1021/cb400430t;
RA   Kim H.G., Tan L., Weisberg E.L., Liu F., Canning P., Choi H.G.,
RA   Ezell S.A., Wu H., Zhao Z., Wang J., Mandinova A., Griffin J.D.,
RA   Bullock A.N., Liu Q., Lee S.W., Gray N.S.;
RT   "Discovery of a potent and selective DDR1 receptor tyrosine kinase
RT   inhibitor.";
RL   ACS Chem. Biol. 8:2145-2150(2013).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 601-913 IN COMPLEXES WITH
RP   INHIBITORS IMATINIB AND PONATINIB, ENZYME REGULATION, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=24768818; DOI=10.1016/j.jmb.2014.04.014;
RA   Canning P., Tan L., Chu K., Lee S.W., Gray N.S., Bullock A.N.;
RT   "Structural mechanisms determining inhibition of the collagen receptor
RT   DDR1 by selective and multi-targeted type II kinase inhibitors.";
RL   J. Mol. Biol. 426:2457-2470(2014).
RN   [33]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-17; ALA-100; GLN-169; ASP-170;
RP   TRP-306 AND ALA-496.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine kinase that functions as cell surface receptor
CC       for fibrillar collagen and regulates cell attachment to the
CC       extracellular matrix, remodeling of the extracellular matrix, cell
CC       migration, differentiation, survival and cell proliferation.
CC       Collagen binding triggers a signaling pathway that involves SRC
CC       and leads to the activation of MAP kinases. Regulates remodeling
CC       of the extracellular matrix by up-regulation of the matrix
CC       metalloproteinases MMP2, MMP7 and MMP9, and thereby facilitates
CC       cell migration and wound healing. Required for normal blastocyst
CC       implantation during pregnancy, for normal mammary gland
CC       differentiation and normal lactation. Required for normal ear
CC       morphology and normal hearing (By similarity). Promotes smooth
CC       muscle cell migration, and thereby contributes to arterial wound
CC       healing. Also plays a role in tumor cell invasion. Phosphorylates
CC       PTPN11. {ECO:0000250, ECO:0000269|PubMed:12065315,
CC       ECO:0000269|PubMed:16234985, ECO:0000269|PubMed:16337946,
CC       ECO:0000269|PubMed:19401332, ECO:0000269|PubMed:20093046,
CC       ECO:0000269|PubMed:20432435, ECO:0000269|PubMed:20884741,
CC       ECO:0000269|PubMed:21044884, ECO:0000269|PubMed:9659899}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Inhibited by the multi-targeted cancer drugs
CC       imatinib and ponatinib. {ECO:0000269|PubMed:24768818}.
CC   -!- SUBUNIT: Homodimer. Interacts (via PPxY motif) with WWC1 (via WW
CC       domains) in a collagen-regulated manner. Forms a tripartite
CC       complex with WWC1 and PRKCZ, but predominantly in the absence of
CC       collagen. Interacts (tyrosine phosphorylated) with SHC1. Interacts
CC       with SRC. Interacts with MYH9. Interacts with CDH1. Interacts with
CC       PTPN11. Interacts with NCK2. {ECO:0000269|PubMed:16337946,
CC       ECO:0000269|PubMed:18190796, ECO:0000269|PubMed:19401332,
CC       ECO:0000269|PubMed:20093046, ECO:0000269|PubMed:20432435,
CC       ECO:0000269|PubMed:22483115, ECO:0000269|PubMed:23899692,
CC       ECO:0000269|PubMed:24509848, ECO:0000269|PubMed:9659899}.
CC   -!- INTERACTION:
CC       O43639:NCK2; NbExp=3; IntAct=EBI-711879, EBI-713635;
CC       Q06124:PTPN11; NbExp=4; IntAct=EBI-711879, EBI-297779;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=CAK I, DDR1b;
CC         IsoId=Q08345-1; Sequence=Displayed;
CC       Name=2; Synonyms=CAK II, DDR1a, Short;
CC         IsoId=Q08345-2; Sequence=VSP_002953;
CC       Name=3; Synonyms=DDR1d;
CC         IsoId=Q08345-4; Sequence=VSP_036916, VSP_036917;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC       Name=4;
CC         IsoId=Q08345-5; Sequence=VSP_038057;
CC       Name=5;
CC         IsoId=Q08345-6; Sequence=VSP_043582, VSP_002953;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Detected in T-47D, MDA-MB-175 and HBL-100
CC       breast carcinoma cells, A-431 epidermoid carcinoma cells, SW48 and
CC       SNU-C2B colon carcinoma cells and Hs 294T melanoma cells (at
CC       protein level). Expressed at low levels in most adult tissues and
CC       is highest in the brain, lung, placenta and kidney. Lower levels
CC       of expression are detected in melanocytes, heart, liver, skeletal
CC       muscle and pancreas. Abundant in breast carcinoma cell lines. In
CC       the colonic mucosa, expressed in epithelia but not in the
CC       connective tissue of the lamina propria. In the thyroid gland,
CC       expressed in the epithelium of the thyroid follicles. In pancreas,
CC       expressed in the islets of Langerhans cells, but not in the
CC       surrounding epithelial cells of the exocrine pancreas. In kidney,
CC       expressed in the epithelia of the distal tubules. Not expressed in
CC       connective tissue, endothelial cells, adipose tissue, muscle cells
CC       or cells of hematopoietic origin. {ECO:0000269|PubMed:7845687,
CC       ECO:0000269|PubMed:7848919, ECO:0000269|PubMed:8247543}.
CC   -!- DOMAIN: The Gly/Pro-rich domains may be required for an unusual
CC       geometry of interaction with ligand or substrates.
CC   -!- PTM: Autophosphorylated in response to fibrillar collagen binding.
CC   -!- PTM: Glycosylation of Asn-211, but apparently not of Asn-260, Asn-
CC       371, or Asn-394, prevents autophosphorylation from occurring in
CC       the absence of collagen. {ECO:0000269|PubMed:22483115,
CC       ECO:0000269|PubMed:24509848}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- CAUTION: The mutant Gln-371 studied is still likely to be
CC       glycosylated at Asn-370, but study did not include mutagenesis of
CC       Asn-370. {ECO:0000305|PubMed:24509848}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=ACF47649.1; Type=Erroneous termination; Positions=287; Note=Translated as Cys.; Evidence={ECO:0000305};
CC       Sequence=BAE06103.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/DDR1ID40280ch6p21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X74979; CAA52915.1; -; mRNA.
DR   EMBL; L11315; AAA02866.1; -; mRNA.
DR   EMBL; Z29093; CAA82335.1; -; mRNA.
DR   EMBL; L20817; AAA18019.1; -; mRNA.
DR   EMBL; U48705; AAC50917.1; -; Genomic_DNA.
DR   EMBL; X98208; CAA66871.1; -; Genomic_DNA.
DR   EMBL; X99023; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99024; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99025; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99026; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99027; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99028; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99029; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99030; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99031; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99032; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99033; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; X99034; CAA66871.1; JOINED; Genomic_DNA.
DR   EMBL; L57508; AAB05208.1; -; mRNA.
DR   EMBL; EU826613; ACF47649.1; ALT_SEQ; mRNA.
DR   EMBL; EU826614; ACF47650.1; -; mRNA.
DR   EMBL; AK291621; BAF84310.1; -; mRNA.
DR   EMBL; AK294793; BAH11886.1; -; mRNA.
DR   EMBL; AB210021; BAE06103.1; ALT_INIT; mRNA.
DR   EMBL; BA000025; BAB63318.1; -; Genomic_DNA.
DR   EMBL; CR759747; CAQ06757.1; -; Genomic_DNA.
DR   EMBL; CR759747; CAQ06756.1; -; Genomic_DNA.
DR   EMBL; AB088102; BAC54935.1; -; Genomic_DNA.
DR   EMBL; AB103608; BAF31270.1; -; Genomic_DNA.
DR   EMBL; AL662854; CAI17434.1; -; Genomic_DNA.
DR   EMBL; AL662870; CAI18441.1; -; Genomic_DNA.
DR   EMBL; AL773541; CAI18450.1; -; Genomic_DNA.
DR   EMBL; AL773589; CAI18450.1; JOINED; Genomic_DNA.
DR   EMBL; AL773589; CAI18534.1; -; Genomic_DNA.
DR   EMBL; AL773541; CAI18534.1; JOINED; Genomic_DNA.
DR   EMBL; AL662854; CAI17433.1; -; Genomic_DNA.
DR   EMBL; AL662870; CAI18442.1; -; Genomic_DNA.
DR   EMBL; AL773541; CAI18451.1; -; Genomic_DNA.
DR   EMBL; AL773589; CAI18451.1; JOINED; Genomic_DNA.
DR   EMBL; AL773589; CAI18533.1; -; Genomic_DNA.
DR   EMBL; AL773541; CAI18533.1; JOINED; Genomic_DNA.
DR   EMBL; AB202100; BAE78621.1; -; Genomic_DNA.
DR   EMBL; BX927194; CAQ09768.1; -; Genomic_DNA.
DR   EMBL; BX927194; CAQ09767.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03335.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03338.1; -; Genomic_DNA.
DR   EMBL; BC008716; AAH08716.1; -; mRNA.
DR   EMBL; BC013400; AAH13400.1; -; mRNA.
DR   EMBL; BC070070; AAH70070.1; -; mRNA.
DR   CCDS; CCDS34385.1; -. [Q08345-1]
DR   CCDS; CCDS4690.1; -. [Q08345-2]
DR   CCDS; CCDS47396.1; -. [Q08345-5]
DR   CCDS; CCDS56411.1; -. [Q08345-6]
DR   PIR; A48280; A48280.
DR   PIR; A49508; A49508.
DR   RefSeq; NP_001189450.1; NM_001202521.1.
DR   RefSeq; NP_001189451.1; NM_001202522.1.
DR   RefSeq; NP_001189452.1; NM_001202523.1. [Q08345-6]
DR   RefSeq; NP_001284581.1; NM_001297652.1. [Q08345-2]
DR   RefSeq; NP_001284582.1; NM_001297653.1. [Q08345-2]
DR   RefSeq; NP_001284583.1; NM_001297654.1. [Q08345-1]
DR   RefSeq; NP_001945.3; NM_001954.4. [Q08345-2]
DR   RefSeq; NP_054699.2; NM_013993.2. [Q08345-1]
DR   RefSeq; NP_054700.2; NM_013994.2. [Q08345-5]
DR   UniGene; Hs.631988; -.
DR   PDB; 3ZOS; X-ray; 1.92 A; A/B=601-913.
DR   PDB; 4AG4; X-ray; 2.80 A; A=29-367.
DR   PDB; 4BKJ; X-ray; 1.70 A; A/B=601-913.
DR   PDB; 4CKR; X-ray; 2.20 A; A=601-913.
DR   PDB; 5BVK; X-ray; 2.29 A; A=595-913.
DR   PDB; 5BVN; X-ray; 2.21 A; A=595-913.
DR   PDB; 5BVO; X-ray; 1.98 A; A=595-913.
DR   PDB; 5BVW; X-ray; 1.94 A; A=595-913.
DR   PDB; 5FDP; X-ray; 2.25 A; A=601-913.
DR   PDB; 5FDX; X-ray; 2.65 A; A/B=601-913.
DR   PDBsum; 3ZOS; -.
DR   PDBsum; 4AG4; -.
DR   PDBsum; 4BKJ; -.
DR   PDBsum; 4CKR; -.
DR   PDBsum; 5BVK; -.
DR   PDBsum; 5BVN; -.
DR   PDBsum; 5BVO; -.
DR   PDBsum; 5BVW; -.
DR   PDBsum; 5FDP; -.
DR   PDBsum; 5FDX; -.
DR   ProteinModelPortal; Q08345; -.
DR   SMR; Q08345; -.
DR   BioGrid; 107234; 15.
DR   DIP; DIP-39698N; -.
DR   IntAct; Q08345; 13.
DR   MINT; MINT-1383336; -.
DR   STRING; 9606.ENSP00000365759; -.
DR   BindingDB; Q08345; -.
DR   ChEMBL; CHEMBL5319; -.
DR   DrugBank; DB00619; Imatinib.
DR   GuidetoPHARMACOLOGY; 1843; -.
DR   iPTMnet; Q08345; -.
DR   PhosphoSitePlus; Q08345; -.
DR   BioMuta; DDR1; -.
DR   DMDM; 729008; -.
DR   MaxQB; Q08345; -.
DR   PaxDb; Q08345; -.
DR   PeptideAtlas; Q08345; -.
DR   PRIDE; Q08345; -.
DR   DNASU; 780; -.
DR   Ensembl; ENST00000259875; ENSP00000259875; ENSG00000137332. [Q08345-2]
DR   Ensembl; ENST00000324771; ENSP00000318217; ENSG00000204580. [Q08345-1]
DR   Ensembl; ENST00000376567; ENSP00000365751; ENSG00000204580. [Q08345-2]
DR   Ensembl; ENST00000376568; ENSP00000365752; ENSG00000204580. [Q08345-1]
DR   Ensembl; ENST00000376569; ENSP00000365753; ENSG00000204580. [Q08345-2]
DR   Ensembl; ENST00000376570; ENSP00000365754; ENSG00000204580. [Q08345-2]
DR   Ensembl; ENST00000376575; ENSP00000365759; ENSG00000204580. [Q08345-4]
DR   Ensembl; ENST00000383377; ENSP00000372868; ENSG00000137332. [Q08345-1]
DR   Ensembl; ENST00000400410; ENSP00000383261; ENSG00000137332. [Q08345-2]
DR   Ensembl; ENST00000400411; ENSP00000383262; ENSG00000137332. [Q08345-2]
DR   Ensembl; ENST00000400414; ENSP00000383265; ENSG00000137332. [Q08345-1]
DR   Ensembl; ENST00000400486; ENSP00000383334; ENSG00000215522. [Q08345-2]
DR   Ensembl; ENST00000400488; ENSP00000383336; ENSG00000215522. [Q08345-2]
DR   Ensembl; ENST00000400489; ENSP00000383337; ENSG00000215522. [Q08345-2]
DR   Ensembl; ENST00000400491; ENSP00000383338; ENSG00000215522. [Q08345-1]
DR   Ensembl; ENST00000400492; ENSP00000383339; ENSG00000215522. [Q08345-1]
DR   Ensembl; ENST00000412329; ENSP00000391805; ENSG00000230456. [Q08345-1]
DR   Ensembl; ENST00000415092; ENSP00000405540; ENSG00000230456. [Q08345-2]
DR   Ensembl; ENST00000418800; ENSP00000407699; ENSG00000204580. [Q08345-2]
DR   Ensembl; ENST00000419412; ENSP00000416183; ENSG00000234078. [Q08345-2]
DR   Ensembl; ENST00000421229; ENSP00000415730; ENSG00000234078. [Q08345-2]
DR   Ensembl; ENST00000427053; ENSP00000416145; ENSG00000230456. [Q08345-2]
DR   Ensembl; ENST00000429699; ENSP00000401397; ENSG00000234078. [Q08345-1]
DR   Ensembl; ENST00000430933; ENSP00000397769; ENSG00000234078. [Q08345-1]
DR   Ensembl; ENST00000449518; ENSP00000414285; ENSG00000230456. [Q08345-1]
DR   Ensembl; ENST00000452441; ENSP00000405039; ENSG00000204580. [Q08345-1]
DR   Ensembl; ENST00000453510; ENSP00000401208; ENSG00000230456. [Q08345-2]
DR   Ensembl; ENST00000454612; ENSP00000406091; ENSG00000204580. [Q08345-2]
DR   Ensembl; ENST00000454774; ENSP00000400393; ENSG00000234078. [Q08345-2]
DR   Ensembl; ENST00000482873; ENSP00000421978; ENSG00000204580. [Q08345-4]
DR   Ensembl; ENST00000508312; ENSP00000422442; ENSG00000204580. [Q08345-6]
DR   Ensembl; ENST00000513240; ENSP00000427552; ENSG00000204580. [Q08345-5]
DR   Ensembl; ENST00000548133; ENSP00000449611; ENSG00000230456. [Q08345-1]
DR   Ensembl; ENST00000548962; ENSP00000448115; ENSG00000230456. [Q08345-6]
DR   Ensembl; ENST00000549026; ENSP00000449238; ENSG00000215522. [Q08345-6]
DR   Ensembl; ENST00000550384; ENSP00000447474; ENSG00000234078. [Q08345-6]
DR   Ensembl; ENST00000550395; ENSP00000449255; ENSG00000215522. [Q08345-1]
DR   Ensembl; ENST00000552068; ENSP00000449190; ENSG00000234078. [Q08345-1]
DR   Ensembl; ENST00000552721; ENSP00000449307; ENSG00000137332. [Q08345-6]
DR   Ensembl; ENST00000553015; ENSP00000448377; ENSG00000137332. [Q08345-1]
DR   Ensembl; ENST00000617572; ENSP00000479195; ENSG00000215522. [Q08345-4]
DR   Ensembl; ENST00000618059; ENSP00000479204; ENSG00000234078. [Q08345-4]
DR   Ensembl; ENST00000620318; ENSP00000484588; ENSG00000137332. [Q08345-4]
DR   Ensembl; ENST00000621544; ENSP00000484013; ENSG00000230456. [Q08345-4]
DR   GeneID; 780; -.
DR   KEGG; hsa:780; -.
DR   UCSC; uc003nrq.4; human. [Q08345-1]
DR   CTD; 780; -.
DR   DisGeNET; 780; -.
DR   GeneCards; DDR1; -.
DR   GeneCards; MIR4640; -.
DR   HGNC; HGNC:2730; DDR1.
DR   HPA; CAB010162; -.
DR   HPA; CAB025656; -.
DR   HPA; HPA057194; -.
DR   MalaCards; DDR1; -.
DR   MIM; 600408; gene.
DR   neXtProt; NX_Q08345; -.
DR   OpenTargets; ENSG00000204580; -.
DR   PharmGKB; PA24348; -.
DR   eggNOG; KOG1094; Eukaryota.
DR   eggNOG; ENOG410XQAI; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000043102; -.
DR   HOVERGEN; HBG005461; -.
DR   InParanoid; Q08345; -.
DR   KO; K05124; -.
DR   OMA; CEVENPQ; -.
DR   OrthoDB; EOG091G05Y8; -.
DR   PhylomeDB; Q08345; -.
DR   TreeFam; TF317840; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   SignaLink; Q08345; -.
DR   SIGNOR; Q08345; -.
DR   ChiTaRS; DDR1; human.
DR   GeneWiki; DDR1; -.
DR   GenomeRNAi; 780; -.
DR   PMAP-CutDB; Q2L6H3; -.
DR   PRO; PR:Q08345; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000137332; -.
DR   CleanEx; HS_DDR1; -.
DR   ExpressionAtlas; Q08345; baseline and differential.
DR   Genevisible; Q08345; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005518; F:collagen binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0038062; F:protein tyrosine kinase collagen receptor activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0061564; P:axon development; IEA:Ensembl.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0038063; P:collagen-activated tyrosine kinase receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043583; P:ear development; IEA:Ensembl.
DR   GO; GO:0007566; P:embryo implantation; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0007595; P:lactation; IEA:UniProtKB-KW.
DR   GO; GO:0060749; P:mammary gland alveolus development; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:1990138; P:neuron projection extension; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0001952; P:regulation of cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0010715; P:regulation of extracellular matrix disassembly; IMP:UniProtKB.
DR   GO; GO:0014909; P:smooth muscle cell migration; IMP:UniProtKB.
DR   GO; GO:0061302; P:smooth muscle cell-matrix adhesion; IMP:UniProtKB.
DR   GO; GO:0044319; P:wound healing, spreading of cells; IMP:UniProtKB.
DR   Gene3D; 2.60.120.260; -; 1.
DR   InterPro; IPR029553; DDR1.
DR   InterPro; IPR000421; FA58C.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   PANTHER; PTHR24416:SF449; PTHR24416:SF449; 1.
DR   Pfam; PF00754; F5_F8_type_C; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00231; FA58C; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01285; FA58C_1; 1.
DR   PROSITE; PS01286; FA58C_2; 1.
DR   PROSITE; PS50022; FA58C_3; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Calcium;
KW   Cell membrane; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Kinase; Lactation; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Pregnancy; Receptor; Reference proteome; Secreted; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    913       Epithelial discoidin domain-containing
FT                                receptor 1.
FT                                /FTId=PRO_0000016742.
FT   TOPO_DOM     21    417       Extracellular. {ECO:0000255}.
FT   TRANSMEM    418    438       Helical. {ECO:0000255}.
FT   TOPO_DOM    439    913       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       31    185       F5/8 type C. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00081}.
FT   DOMAIN      610    905       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     616    624       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      192    367       DS-like domain.
FT   MOTIF       481    484       PPxY motif.
FT   COMPBIAS    377    415       Gly/Pro-rich.
FT   COMPBIAS    476    601       Gly/Pro-rich.
FT   ACT_SITE    766    766       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   METAL       211    211       Calcium 1; via carbonyl oxygen.
FT   METAL       230    230       Calcium 1.
FT   METAL       230    230       Calcium 2; via carbonyl oxygen.
FT   METAL       233    233       Calcium 2.
FT   METAL       235    235       Calcium 2; via carbonyl oxygen.
FT   METAL       253    253       Calcium 1; via carbonyl oxygen.
FT   METAL       255    255       Calcium 1; via carbonyl oxygen.
FT   METAL       360    360       Calcium 2; via carbonyl oxygen.
FT   METAL       361    361       Calcium 2.
FT   BINDING     655    655       ATP.
FT   MOD_RES     484    484       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MOD_RES     513    513       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:24509848,
FT                                ECO:0000269|PubMed:9659899}.
FT   MOD_RES     520    520       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MOD_RES     631    631       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     740    740       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:16337946}.
FT   MOD_RES     792    792       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MOD_RES     796    796       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MOD_RES     797    797       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:24509848}.
FT   CARBOHYD    211    211       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:22483115,
FT                                ECO:0000269|PubMed:24509848}.
FT   CARBOHYD    260    260       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:22483115,
FT                                ECO:0000269|PubMed:24509848}.
FT   CARBOHYD    370    370       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    371    371       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    394    394       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     31    185       {ECO:0000255|PROSITE-ProRule:PRU00081,
FT                                ECO:0000269|PubMed:22483115}.
FT   DISULFID     74    177       {ECO:0000255|PROSITE-ProRule:PRU00081,
FT                                ECO:0000269|PubMed:22483115}.
FT   DISULFID    303    348       {ECO:0000255|PROSITE-ProRule:PRU00081,
FT                                ECO:0000269|PubMed:22483115}.
FT   VAR_SEQ       1      1       M -> MSLPRCCPHPLRPEGSGAM (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_043582.
FT   VAR_SEQ     190    243       GLLSYTAPVGQTMYLSEAVYLNDSTYDGHTVGGLQYGGLGQ
FT                                LADGVVGLDDFRK -> CSMGVWASWQMVWWGWMTLGRVRS
FT                                CGSGQAMTMWDGATTASPVAMWRWSLSLTG (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_036916.
FT   VAR_SEQ     244    913       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_036917.
FT   VAR_SEQ     506    542       Missing (in isoform 2 and isoform 5).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7845687,
FT                                ECO:0000303|PubMed:7848919,
FT                                ECO:0000303|PubMed:8226977,
FT                                ECO:0000303|PubMed:8622863,
FT                                ECO:0000303|Ref.10}.
FT                                /FTId=VSP_002953.
FT   VAR_SEQ     665    665       A -> ASFSLFS (in isoform 4).
FT                                {ECO:0000303|PubMed:7845687}.
FT                                /FTId=VSP_038057.
FT   VARIANT      17     17       S -> G (in dbSNP:rs55901302).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041492.
FT   VARIANT     100    100       V -> A (in dbSNP:rs34544756).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041493.
FT   VARIANT     169    169       R -> Q (in dbSNP:rs55980643).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041494.
FT   VARIANT     170    170       A -> D (in dbSNP:rs56231803).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041495.
FT   VARIANT     306    306       R -> W (in dbSNP:rs56024191).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041496.
FT   VARIANT     496    496       S -> A (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041497.
FT   VARIANT     833    833       L -> V (in dbSNP:rs2524235).
FT                                {ECO:0000269|PubMed:8390675,
FT                                ECO:0000269|PubMed:8977099}.
FT                                /FTId=VAR_049716.
FT   MUTAGEN     105    105       R->A: Inhibits collagen-induced
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     211    211       N->A: Phosphorylates regardless of
FT                                collagen presence, collagen addition does
FT                                not alter significantly the levels of
FT                                constitutive phosphorylation.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     211    211       N->Q: Sustained phosphorylation
FT                                regardless of collagen presence, collagen
FT                                addition does not alter significantly the
FT                                levels of constitutive phosphorylation.
FT                                Located intracellularly and at the cell
FT                                surface. Displays a reduced rate of
FT                                receptor internalization, which is not
FT                                altered in the presence of collagen. Able
FT                                to bind collagen as wild-type. Exhibits
FT                                enhanced collagen-independent receptor
FT                                dimerization. Complete loss of the
FT                                collagen-independent constitutive
FT                                activation; when associated with A-655.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     213    213       S->A: Phosphorylates regardless of
FT                                collagen presence, collagen addition does
FT                                not alter significantly the levels of
FT                                constitutive phosphorylation.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     260    260       N->Q: Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type. No activation in the absence
FT                                of collagen.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     371    371       N->Q: Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type. No activation in the absence
FT                                of collagen.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     379    379       T->A: Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type. Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type; when associated with A-393.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     393    393       T->A: Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type. Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type; when associated with A-379.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     394    394       N->Q: Phosphorylates in response to
FT                                collagen, but at lower levels compared to
FT                                wild-type. No activation in the absence
FT                                of collagen.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     655    655       K->A: Loss of kinase activity. Complete
FT                                loss of the collagen-independent
FT                                constitutive activation; when associated
FT                                with Q-211.
FT                                {ECO:0000269|PubMed:24509848}.
FT   MUTAGEN     707    707       G->A: Confers over 20-fold resistance to
FT                                the ability of an inhibitor to inhibit
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:23899692}.
FT   MUTAGEN     740    740       Y->F: Abolishes interaction with PTPN11.
FT                                {ECO:0000269|PubMed:16337946}.
FT   CONFLICT     94     94       L -> V (in Ref. 2; AAA02866 and 5;
FT                                AAC50917). {ECO:0000305}.
FT   CONFLICT    165    165       R -> H (in Ref. 14; AAH70070).
FT                                {ECO:0000305}.
FT   CONFLICT    285    286       VH -> MW (in Ref. 8; ACF47649).
FT                                {ECO:0000305}.
FT   CONFLICT    741    741       P -> Q (in Ref. 14; AAH70070).
FT                                {ECO:0000305}.
FT   CONFLICT    847    867       QLTDEQVIENAGEFFRDQGRQ -> SAHRRAGHRERGGVLP
FT                                GPGPA (in Ref. 6; CAA66871).
FT                                {ECO:0000305}.
FT   TURN         37     39       {ECO:0000244|PDB:4AG4}.
FT   HELIX        44     46       {ECO:0000244|PDB:4AG4}.
FT   STRAND       47     50       {ECO:0000244|PDB:4AG4}.
FT   HELIX        55     57       {ECO:0000244|PDB:4AG4}.
FT   HELIX        59     61       {ECO:0000244|PDB:4AG4}.
FT   TURN         68     70       {ECO:0000244|PDB:4AG4}.
FT   STRAND       71     73       {ECO:0000244|PDB:4AG4}.
FT   STRAND       87    103       {ECO:0000244|PDB:4AG4}.
FT   HELIX       107    109       {ECO:0000244|PDB:4AG4}.
FT   STRAND      116    127       {ECO:0000244|PDB:4AG4}.
FT   STRAND      129    131       {ECO:0000244|PDB:4AG4}.
FT   STRAND      145    148       {ECO:0000244|PDB:4AG4}.
FT   STRAND      151    169       {ECO:0000244|PDB:4AG4}.
FT   STRAND      171    173       {ECO:0000244|PDB:4AG4}.
FT   STRAND      178    186       {ECO:0000244|PDB:4AG4}.
FT   STRAND      191    197       {ECO:0000244|PDB:4AG4}.
FT   STRAND      204    206       {ECO:0000244|PDB:4AG4}.
FT   STRAND      217    220       {ECO:0000244|PDB:4AG4}.
FT   STRAND      223    226       {ECO:0000244|PDB:4AG4}.
FT   HELIX       230    232       {ECO:0000244|PDB:4AG4}.
FT   STRAND      245    248       {ECO:0000244|PDB:4AG4}.
FT   TURN        251    254       {ECO:0000244|PDB:4AG4}.
FT   STRAND      256    259       {ECO:0000244|PDB:4AG4}.
FT   HELIX       260    262       {ECO:0000244|PDB:4AG4}.
FT   STRAND      266    287       {ECO:0000244|PDB:4AG4}.
FT   HELIX       291    293       {ECO:0000244|PDB:4AG4}.
FT   STRAND      299    306       {ECO:0000244|PDB:4AG4}.
FT   STRAND      308    312       {ECO:0000244|PDB:4AG4}.
FT   STRAND      314    316       {ECO:0000244|PDB:4AG4}.
FT   STRAND      318    321       {ECO:0000244|PDB:4AG4}.
FT   STRAND      332    351       {ECO:0000244|PDB:4AG4}.
FT   STRAND      353    367       {ECO:0000244|PDB:4AG4}.
FT   HELIX       607    609       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      610    619       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      622    631       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       632    634       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      637    639       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      651    657       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       663    678       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      687    691       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      693    696       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      698    702       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       709    714       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       740    759       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       769    771       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      772    774       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       776    778       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      780    782       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       790    795       {ECO:0000244|PDB:4BKJ}.
FT   STRAND      797    800       {ECO:0000244|PDB:3ZOS}.
FT   STRAND      803    805       {ECO:0000244|PDB:3ZOS}.
FT   HELIX       807    809       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       812    817       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       822    837       {ECO:0000244|PDB:4BKJ}.
FT   TURN        838    840       {ECO:0000244|PDB:4BKJ}.
FT   TURN        844    847       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       850    862       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       878    887       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       892    894       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       898    906       {ECO:0000244|PDB:4BKJ}.
FT   TURN        907    909       {ECO:0000244|PDB:4BKJ}.
FT   HELIX       910    912       {ECO:0000244|PDB:4BKJ}.
SQ   SEQUENCE   913 AA;  101128 MW;  C96913EA906C481E CRC64;
     MGPEALSSLL LLLLVASGDA DMKGHFDPAK CRYALGMQDR TIPDSDISAS SSWSDSTAAR
     HSRLESSDGD GAWCPAGSVF PKEEEYLQVD LQRLHLVALV GTQGRHAGGL GKEFSRSYRL
     RYSRDGRRWM GWKDRWGQEV ISGNEDPEGV VLKDLGPPMV ARLVRFYPRA DRVMSVCLRV
     ELYGCLWRDG LLSYTAPVGQ TMYLSEAVYL NDSTYDGHTV GGLQYGGLGQ LADGVVGLDD
     FRKSQELRVW PGYDYVGWSN HSFSSGYVEM EFEFDRLRAF QAMQVHCNNM HTLGARLPGG
     VECRFRRGPA MAWEGEPMRH NLGGNLGDPR ARAVSVPLGG RVARFLQCRF LFAGPWLLFS
     EISFISDVVN NSSPALGGTF PPAPWWPPGP PPTNFSSLEL EPRGQQPVAK AEGSPTAILI
     GCLVAIILLL LLIIALMLWR LHWRRLLSKA ERRVLEEELT VHLSVPGDTI LINNRPGPRE
     PPPYQEPRPR GNPPHSAPCV PNGSALLLSN PAYRLLLATY ARPPRGPGPP TPAWAKPTNT
     QAYSGDYMEP EKPGAPLLPP PPQNSVPHYA EADIVTLQGV TGGNTYAVPA LPPGAVGDGP
     PRVDFPRSRL RFKEKLGEGQ FGEVHLCEVD SPQDLVSLDF PLNVRKGHPL LVAVKILRPD
     ATKNARNDFL KEVKIMSRLK DPNIIRLLGV CVQDDPLCMI TDYMENGDLN QFLSAHQLED
     KAAEGAPGDG QAAQGPTISY PMLLHVAAQI ASGMRYLATL NFVHRDLATR NCLVGENFTI
     KIADFGMSRN LYAGDYYRVQ GRAVLPIRWM AWECILMGKF TTASDVWAFG VTLWEVLMLC
     RAQPFGQLTD EQVIENAGEF FRDQGRQVYL SRPPACPQGL YELMLRCWSR ESEQRPPFSQ
     LHRFLAEDAL NTV
//
